Also trades as: 22UA.F (FSX) · $vol 4M
BNTX NASDAQ
BioNTech SE
1W: -4.5%
1M: -12.1%
3M: -6.3%
YTD: -10.0%
1Y: -17.6%
3Y: -4.2%
5Y: -66.4%
$87.06
+0.20 (+0.23%)
Weekly Expected Move ±5.6%
$78
$83
$88
$93
$98
Credit Risk of going bust: lower than 81% of companies Debt: 1.6% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.17 (down 99.8%), BioNTech SE would be worth roughly what it owes.
Total debt $351.7M against a stock market value of $21.87B.
Distance to default 9.98 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $207.7M (short-term plus half of long-term), stock volatility 46.5%; Altman Z'' 13.64. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $351.7M against a stock market value of $21.87B.
Distance to default 9.98 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $207.7M (short-term plus half of long-term), stock volatility 46.5%; Altman Z'' 13.64. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
📊 Key Metrics
TTM$3B
Revenue
-8.2% YoY
$-1,692M
Net Income
-390.8% YoY
$518M
Free Cash Flow
+124.1% YoY
8.1%
Gross Margin
-897.8%
Op. Margin
-777.3%
Net Margin
💰 Income Flow
How revenue becomes profit💵 Cash Flow
Where cash goes🏦 Balance Sheet
Assets = Liabilities + Equity📈 Financial Health
Profitability
ROE-9.3%
ROA-8.1%
ROIC-18.0%
Valuation
P/E-11.5
P/B1.1
EV/EBITDA0.0
Leverage
Debt/Equity0.02
Current Ratio7.85
Interest Cov.-86.0x
Quality Scores
Piotroski F2/9
Altman Z—
Beneish M-0.55